Table 1.
Clinical data on paediatric patients included in the in vitro cisapride metabolic study.
| Patient | Postnatal age (days) | Gestational age (weeks) | Pathology |
|---|---|---|---|
| Fœtus 1 | 20 | Spontaneous abortion | |
| Fœtus 2 | 31 | Therapeutic abortion for Down syndrome | |
| Fœtus 3 | 33 | Therapeutic abortion for urinary tract malformations | |
| Fœtus 4 | 33 | Therapeutic abortion for myelomeningocoele | |
| Neonate 1 | 1 | 28 | Down syndrome sepsis |
| Neonate 2 | 2 | 33 | Respiratory distress |
| Neonate 3 | 5 | 28 | Hyaline membrane disease |
| Neonate 4 | 7 | 29 | Hyaline membrane disease |
| Neonate 5 | 35 | N.A. | Sudden infant death |
| Neonate 6 | 47 | 40 | Sudden infant death |
| Neonate 7 | 90 | N.A. | Sudden infant death |
| Neonate 8 | 90 | N.A. | Sudden infant death |
| Neonate 9 | 183 | 38 | Sudden infant death |
N.A. not available.